Areyl Goff, APNP

In this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.

In this segment, Dr Mohan asks Dr Nadeem about the real-world performance of elranatamab, its advantages and challenges in clinical practice, and the next therapeutic approach if a patient experiences disease progression on elranatamab.

In this segment, Dr. Mohan asks Dr. Mann to summarize the key efficacy data from the MagnestisMM trials evaluating the use of elranatamab in relapsed/refractory multiple myeloma (R/R MM).

Dr Mohan asks Dr Nadeem about the selection process among bispecific antibodies, the factors influencing decision-making, and the use of talquetamab, teclistamab, or elranatamab in specific patient subgroups, followed by a discussion with Dr Mann on next therapeutic steps if a patient experiences disease progression on talquetamab.

Dr Mohan and Dr Mann discuss the current therapeutic landscape for relapsed/refractory multiple myeloma (R/R MM), alternative treatment strategies, and the real-world performance, advantages, and challenges of incorporating talquetamab into treatment protocols.

Dr Nadeem to summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma, including key efficacy outcomes from the monumenTAL trials.

68-year-old male construction worker with a long history of multiple myeloma, managing multiple lines of treatment including BCMA-directed CAR T therapy, alongside a history of hypertension, respiratory infections, and type 2 diabetes, now receiving talquetamab.